A randomised, double-blind, placebo controlled study of the broader efficacy of atomoxetine hydrochloride in the treatment of attention-deficit/hyperactivity disorder (ADHD) in Swedish children and adolescents
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 16 Oct 2006 Status change
- 28 Jul 2006 Status change
- 11 Nov 2005 New trial record.